Comparison · NCT03275350-sae
Extended-release Naltrexone (XR-NTX) vs Treatment as Usual (TAU): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Extended-release Naltrexone (XR-NTX) vs Treatment as Usual (TAU): serious adverse events. Trial comparisons, record NCT03275350-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03275350-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0909 | 0.0395 | 0.196 | wilson | |
| Risk in group 2 | 0.119 | 0.0587 | 0.225 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0277 | -0.146 | 0.0931 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.766 | 0.258 | 2.27 | log | |
| Odds ratio, group 1 over group 2 | 0.743 | 0.221 | 2.49 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Extended-release Naltrexone (XR-NTX) than on Treatment as Usual (TAU) | 36.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Extended-release Naltrexone (XR-NTX) | Extended-release naltrexone~Naltrexone Injectable Suspension: Six monthly injections of extended-release naltrexone | 5 | 55 | EG000 |
| Group 2 | Treatment as Usual (TAU) | Treatment as usual~Treatment as usual: Standard treatment for opioid use disorder provided at each HIV clinic | 7 | 59 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 24 weeks
Source ClinicalTrials.gov
Trial
- Title
- Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up
- NCT number
- NCT03275350
- Phases
- PHASE2, PHASE3
- Conditions
- Opioid-use Disorder, Hiv
- Interventions
- Naltrexone Injectable Suspension, Treatment as usual
- Lead sponsor
- Oregon Health and Science University
- Results first posted
- 2022-04-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03275350?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03275350-sae